Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)It is predicted that the State Council Press Office will hold a press conference at 10 am on Monday, December 16th, 2024, and ask Fu Linghui, spokesperson of the National Bureau of Statistics and head of the National Economic Statistics Department, to introduce the national economic operation in November 2024 and answer questions from reporters.Spain's CPI monthly rate in November was 0.2%, expected to be 0.2%, and the previous value was 0.20%. Spain's CPI annual rate in November ended at 2.4%, with an expected 2.4% and a previous value of 2.40%. Spain reconciled CPI monthly rate in November with the final value of 0%, the expected value of 0% and the previous value of 0.00%. Spain's November harmonized CPI annual rate ended at 2.4%, with an expected 2.4% and a previous value of 2.40%.
Wang Honghai, former chairman of the Financial and Economic Committee of Tianjin Municipal People's Congress, was "double-opened" for illegal intervention and intervention in judicial activities. Recently, with the approval of the Tianjin Municipal Committee of the Communist Party of China, the Supervision Committee of Tianjin Municipal Commission for Discipline Inspection filed a case review and investigation on Wang Honghai, former member of the Standing Committee of the Municipal People's Congress, former chairman of the Financial and Economic Committee of the Municipal People's Congress and former director of the Budget Working Committee of the Standing Committee of the Municipal People's Congress. After investigation, Wang Honghai lost his ideals and beliefs, abandoned his initial mission, resisted organizational censorship, and personally engaged in superstitious activities; Ignoring the spirit of the eight central regulations, repeatedly accepting gifts and gifts in violation of regulations, arranging family members to accept tourism activities that may affect the fair execution of official duties, and borrowing vehicles for management services for a long time without compensation; Violation of organizational principles, using authority to seek benefits for others in the promotion and adjustment of cadres' positions; Violation of regulations and intervention in judicial activities, improper performance of duties in the work, resulting in adverse effects; Taking public power as a tool for personal gain, taking advantage of his position to make profits for others in project contracting and job transfer, and illegally accepting huge amounts of property.Baiyun Airport: The passenger throughput in the first November increased by 21.16% year-on-year. Baiyun Airport (600004) released the November production and operation data express on the evening of December 13th, and Baiyun Airport took 43,637 flights (sorties) in November, up by 12.94% year-on-year. Passenger throughput was 6,504,400 person-times, up by 19.94% year-on-year; The cargo and mail throughput was 212,100 tons, a year-on-year increase of 5.68%. Baiyun Airport took off and landed 465,983 sorties from January to November, up 12.05% year-on-year; The passenger throughput was 69.6674 million person-times, up by 21.16% year-on-year; The cargo and mail throughput was 2,161,300 tons, up 18.12% year-on-year.Kunlun Unicom and Anheng Information signed a cooperation agreement. On December 11th, Beijing Kunlun Unicom Technology Development Co., Ltd. and Anheng Information signed a cooperation agreement for Beijing regional general generation in Beijing. In this cooperation, Kunlun Unicom will rely on Anheng Information's professional technology and products in the field of digital security to further enrich its solution system and provide customers with more comprehensive information technology services. At the same time, Anheng Information will also rely on Kunlun Unicom's extensive customer resources and market channels to expand its market business in Beijing.
European stocks opened slightly lower, with the Stoxx 50 index in Europe down 0.1%, DAX index in Germany up 0.2%, FTSE 100 index in Britain down 0.1% and CAC 40 index in France down 0.1%.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14